{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:46Z","timestamp":1783416346169,"version":"3.54.6"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study aimed to evaluate the 10-year outcomes and efficacy of intravitreal injection (IVI) of ranibizumab for treatment of myopic choroidal neovascularization (CNV). This retrospective study included 12 consecutive eyes with myopic CNV treated with ranibizumab with a minimum follow-up of 10 years. The primary outcome was the mean change in best corrected visual acuity (BCVA). The secondary outcomes were Snellen line visual acuity distribution, number of IVIs, and changes in areas of chorioretinal patchy atrophy. The mean number of IVIs was 4.92\u2005\u00b1\u20055.93 (range, 1\u201323). The mean BCVA at baseline was 0.49\u2005\u00b1\u20050.54 logMAR; it improved to 0.29\u2005\u00b1\u20050.38(\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.017), 0.40\u2005\u00b1\u20050.39(\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.186), 0.32\u2005\u00b1\u20050.41 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.087), 0.49\u2005\u00b1\u20050.40 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.643), 0.45\u2005\u00b1\u20050.51 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.817) logMAR at 1, 3, 5, 6, and 10 years, respectively. At baseline and 10 years, 8.3% of eyes had a BCVA of 6\/60 or worse, and 58.33% and 50% of eyes had a BCVA of 6\/12 or better, respectively. The 3-month loading protocol was significantly associated with a Snellen visual acuity gain of &gt;3 lines at 5 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.035); however, the association was lost at 10 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.371). Patchy atrophy increased in 5 eyes (41.67%) after 10 years. Intravitreal ranibizumab injections provided favorable and safe 10-year visual outcomes for myopic CNV. These results are notably superior to the 10-year natural history previously reported in Japanese patients, suggesting that long-term anti-VEGF therapy can effectively preserve vision in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048925","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:01:14Z","timestamp":1779469274000},"page":"e48925","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization"],"prefix":"10.1097","volume":"105","author":[{"given":"Ya-Hsin","family":"Kung","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Ling","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Yang","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Tien","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients.","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia.","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","article-title":"Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month randomized, double-masked study.","volume":"39","author":"Chen","year":"2019","journal-title":"Retina"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia.","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.","volume":"33","author":"Wang","year":"2013","journal-title":"Retina"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.survophthal.2014.10.002","article-title":"The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents.","volume":"60","author":"Adatia","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/jop.2011.0106","article-title":"The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.","volume":"28","author":"Wu","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/jop.2014.0033","article-title":"Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization.","volume":"30","author":"Wu","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1097\/IAE.0000000000001453","article-title":"Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization.","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/OPTH.S49437","article-title":"Current and emerging treatment options for myopic choroidal neovascularization.","volume":"9","author":"El Matri","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":"Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.","volume":"27","author":"Tufail","year":"2013","journal-title":"Eye (Lond)"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41433-018-0192-2","article-title":"Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan.","volume":"32","author":"Ohno-Matsui","year":"2018","journal-title":"Eye (Lond)"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"e0227557","DOI":"10.1371\/journal.pone.0227557","article-title":"Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study.","volume":"15","author":"Hamilton","year":"2020","journal-title":"PLoS One"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","article-title":"Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia.","volume":"39","author":"Onishi","year":"2019","journal-title":"Retina"},{"key":"R19-20260707","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up.","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R20-20260707","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1167\/iovs.17-22633","article-title":"Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization.","volume":"58","author":"Parravano","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20260707","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","article-title":"Myopic choroidal neovascularisation: current concepts and update on clinical management.","volume":"99","author":"Wong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R22-20260707","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R23-20260707","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2147\/OPTH.S311816","article-title":"Real-world anti-vascular endothelial growth factor therapy outcomes in myopic choroidal neovascularization.","volume":"15","author":"Bhatia","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R24-20260707","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":"Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.","volume":"97","author":"Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:01:20Z","timestamp":1783414880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":24,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048925","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-11-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}